Close-up portrait of a man looking into the camera
About us

THERAPEUTIC DERMATOLOGY

The Therapeutic Dermatology market segment encompasses prescription treatments that target moderate to severe skin conditions, from acne to skin cancer.

Galderma maintains a broad portfolio and a commitment to developing new therapies in diverse disease areas with unmet medical needs. We hold leading positions in acne, rosacea and non-melanoma skin cancer treatments, and the continued investigation of therapies for other skin conditions such as prurigo nodularis and atopic dermatitis will further strengthen our Therapeutic Dermatology portfolio.

 

 

INNOVATION

 

Continuous innovation is key as we work toward our bold ambition to become the leading dermatology company in the world.

Our R&D teams work relentlessly—with a focus on biotechnologies for injectable and oral products—to help ensure we meet individual consumer and patient needs with superior outcomes.

We have developed a best-in-class pipeline and a track record of first-to-market innovation. A key priority is advancing a biologic monoclonal antibody to address unmet need in prurigo nodularis and atopic dermatitis.

In August 2024, the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of adults with prurigo nodularis and, in December 2024, for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis. Nemluvio was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. FDA – a status reserved for medicines with the potential to significantly improve the treatment of serious conditions.

 

OUR INJECTABLE AESTHETICS SOLUTIONS

close-up portrait of a middle-aged woman laughing
Read more

OUR DERMATOLOGICAL SKINCARE SOLUTIONS

Portrait shot of a black woman laughing
Read more

OUR BRANDS

Galderma_Content Images_Our Brands_4.png
Read more